22:00 , Jul 3, 2019 |  BC Extra  |  Preclinical News

Controlling CAR T toxicity with BMS's Sprycel

Bristol-Myers Squibb’s leukemia drug Sprycel could stop CAR T associated cytokine release syndrome at the root without the need for engineered control features like off-switches. One of the main limitations of CAR T cell therapy...
18:06 , Oct 19, 2018 |  BC Week In Review  |  Company News

Xyphos, Parker Institute steer next-gen Car T therapies into solid tumors

Xyphos Biosciences Inc. (South San Francisco, Calif.) will partner with the Parker Institute for Cancer Immunotherapy to develop CAR Ts using Xyphos' convertible CAR platform. Xyphos President and CEO Jim Knighton told BioCentury the research...
14:01 , Oct 18, 2018 |  BC Extra  |  Company News

Xyphos, Parker Institute steer next-gen CAR T therapies into solid tumors

Xyphos Biosciences Inc. (South San Francisco, Calif.) will partner with the Parker Institute for Cancer Immunotherapy to develop CAR Ts using Xyphos' convertible CAR platform. Xyphos President and CEO Jim Knighton told BioCentury the research...
04:21 , Dec 8, 2017 |  BC Week In Review  |  Company News

AvidBiotics splits in two

In November, AvidBiotics Corp (South San Francisco, Calif.) said it will split into two separate entities. One company, Xyphos Inc., will develop its chimeric antigen receptor (CAR) T cell platform, convertible CAR, for immuno-oncology applications....
17:54 , Nov 1, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: October 2017

New Therapeutic Targets and Biomarkers: October 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during October 2017. Therapeutic targets are defined as any protein, gene or other...
23:17 , Oct 5, 2017 |  BC Innovations  |  Product R&D

Avidly specific

With its first two programs headed for the clinic next year, AvidBiotics Corp. is seeing the fruits of its move to human therapeutics from food safety and animal health. Using engineered peptides, the company has...
07:00 , Jul 10, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Dermatology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Dermatology Wounds c-Met proto-oncogene (MET; HGFR); hepatocyte growth factor/scatter factor (HGF/SF) In vitro studies suggest allosteric zymogen activator peptides that stimulate MET signaling could help treat...
07:00 , Oct 1, 2012 |  BC Week In Review  |  Company News

AvidBiotics, E. I. du Pont de Nemours and Co. deal

AvidBiotics granted DuPont exclusive, worldwide rights to AvidBiotics' Purocin antibacterial protein technology for food safety applications. As a part of the deal, DuPont Ventures made an equity investment in AvidBiotics. AvidBiotics, which retains rights to...
07:00 , Mar 12, 2012 |  BC Week In Review  |  Clinical News

AvidBiotics preclinical data

AvidBiotic's Avidocin proteins are genetically engineered from R-type pyocins, which are antibacterial proteins produced by some Pseudomonas aeruginosa strains. The company said the proteins specifically kill bacteria by binding to the bacterial cell and creating...
07:00 , Sep 28, 2009 |  BioCentury  |  Politics, Policy & Law

The Counterattack

Even though the Senate Finance Committee will continue debating amendments to its healthcare reform legislation this week, much of the focus for pharmaceutical and biotech companies has already shifted to the next legislative inflection points...